Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:FUSN

Fusion Pharmaceuticals (FUSN) Stock Price, News & Analysis

Fusion Pharmaceuticals logo

About Fusion Pharmaceuticals Stock (NASDAQ:FUSN)

Advanced Chart

Key Stats

Today's Range
$21.55
$21.55
50-Day Range
$21.38
$21.55
52-Week Range
$2.31
$21.60
Volume
N/A
Average Volume
1.69 million shs
Market Capitalization
$1.83 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive FUSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

FUSN Stock News Headlines

Fusion Pharma Stock Price History
This Cold War “Accident” Could Unleash New $100 Trillion AI Boom
Obscure Metal More Valuable than Gold and Bitcoin… COMBINED? This strange "AI Metal" holds the key to the $100 trillion AI boom. Which is why Jeff Brown recently traveled to a location that has one of the highest concentrations of this metal in the world. And you won't believe what he uncovered.
Fusion Finance Ltd (FUSN)
Fusion Pharma (FUSN) Earnings Dates & Reports
Acquisition of Fusion Pharmaceuticals Completed
See More Headlines

FUSN Stock Analysis - Frequently Asked Questions

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) released its earnings results on Tuesday, November, 9th. The company reported ($0.45) EPS for the quarter, topping analysts' consensus estimates of ($0.58) by $0.13. The firm had revenue of $0.33 million for the quarter. Fusion Pharmaceuticals had a negative trailing twelve-month return on equity of 48.74% and a negative net margin of 4,136.55%.

Fusion Pharmaceuticals (FUSN) raised $126 million in an initial public offering on Friday, June 26th 2020. The company issued 8,400,000 shares at $14.00-$16.00 per share. Morgan Stanley, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Fusion Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Novo Nordisk A/S (NVO), Super Micro Computer (SMCI) and ServiceNow (NOW).

Company Calendar

Last Earnings
11/09/2021
Today
7/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:FUSN
CIK
1805890
Fax
N/A
Employees
101
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.42)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$94.90 million
Net Margins
-4,136.55%
Pretax Margin
-5,084.07%
Return on Equity
-48.74%
Return on Assets
-36.87%

Debt

Debt-to-Equity Ratio
0.21
Current Ratio
10.64
Quick Ratio
10.64

Sales & Book Value

Annual Sales
$2.07 million
Price / Sales
885.53
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.07 per share
Price / Book
7.02

Miscellaneous

Outstanding Shares
85,060,000
Free Float
78,468,000
Market Cap
$1.83 billion
Optionable
Optionable
Beta
-0.69
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:FUSN) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners